Abstract:Hormones play a crucial role in maintaining the normal human physiology. By acting as chemical messengers that facilitate the communication between different organs, tissues and cells of the body hormones assist in responding appropriately to external and internal stimuli that trigger growth, development and metabolic activities of the body. Any abnormalities in the hormonal composition and balance can lead to devastating health consequences. Hormones have been important therapeutic agents since the early 20th century, when it was realized that their exogenous supply could serve as a functional substitution for those hormones which are not produced enough or are completely lacking, endogenously. Insulin, the pivotal anabolic hormone in the body, was used for the treatment of diabetes mellitus, a metabolic disorder due to the absence or intolerance towards insulin, since 1921 and is the trailblazer in hormone therapeutics. At present the largest market share for therapeutic hormones is held by insulin. Many other hormones were introduced into clinical practice following the success with insulin. However, for the six decades following the introduction the first therapeutic hormone, there was no reliable method for producing human hormones. The most common source for hormones were animals, although semisynthetic and synthetic hormones were also developed. However, none of these were optimal because of their allergenicity, immunogenicity, lack of consistency in purity and most importantly, scalability. The advent of recombinant DNA technology was a game changer for hormone therapeutics. This revolutionary molecular biology tool made it possible to synthesize human hormones in microbial cell factories. The approach allowed for the synthesis of highly pure hormones which were structurally and biochemically identical to the human hormones. Further, the fermentation techniques utilized to produce recombinant hormones were highly scalable. Moreover, by employing tools such as site directed mutagenesis along with recombinant DNA technology, it became possible to amend the molecular structure of the hormones to achieve better efficacy and mimic the exact physiology of the endogenous hormone. The first recombinant hormone to be deployed in clinical practice was insulin. It was called biosynthetic human insulin to reflect the biological route of production. Subsequently, the biochemistry of recombinant insulin was modified using the possibilities of recombinant DNA technology and genetic engineering to produce analogues that better mimic physiological insulin. These analogues were tailored to exhibit pharmacokinetic and pharmacodynamic properties of the prandial and basal human insulins to achieve better glycemic control. The present chapter explores the principles of genetic engineering applied to therapeutic hormones by reviewing the evolution of therapeutic insulin and its analogues. It also focuses on how recombinant analogues account for the better management of diabetes mellitus.

Insulin’s Legacy: A Century of Breakthroughs and Innovation

Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

Celebration of a century of insulin therapy in children with type 1 diabetes

100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future

Insulin discovery: A pivotal point in medical history

A Hundred Years of Insulin Innovation: When Science Meets Technology

Insulin and Its Single-Chain Analogue

One hundred years ago: the dawning of the insulin era

Insulin’s Discovery: New Insights on Its Hundredth Birthday: From Insulin Action and Clearance to Sweet Networks

Current and Future Strategies in Insulin Development and Treatment

The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond

Advancements in Oral Insulin: A Century of Research and the Emergence of Targeted Nanoparticle Strategies

History of insulin

Realizing Better Diabetes Outcomes Through a Diabetes Data Revolution

Development and Future of Automated Insulin Delivery (AID) Systems

Insulin analogs in the treatment of type II diabetes and future perspectives

Sixty Years of Confronting Diabetes and Kidney Disease

Biotechnology Revolution Shaping the Future of Diabetes Management

A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries

Recent Advances and Perspectives in Novel Insulin Release Systems

Evolution of biosynthetic human insulin and its analogues for diabetes management